2024
Disparities in Receipt of Medications for Opioid Use Disorder Before and During the COVID-19 Pandemic in the US Veterans Health Administration.
Sung M, León C, Reisman J, Gordon K, Kerns R, Li W, Liu W, Mitra A, Yu H, Becker W. Disparities in Receipt of Medications for Opioid Use Disorder Before and During the COVID-19 Pandemic in the US Veterans Health Administration. Substance Use & Addiction Journal 2024, 29767342241293334. PMID: 39569566, DOI: 10.1177/29767342241293334.Peer-Reviewed Original ResearchMOUD receiptElixhauser Comorbidity IndexOpioid use disorderSocial determinants of healthVeterans Health Administration electronic health record dataElectronic health record dataUS Veterans Health AdministrationDeterminants of healthVeterans Health AdministrationHealth record dataProportion of veteransReceipt of medicationsSubstance useComorbidity indexTargeted outreach effortsUse disorderCOVID-19 pandemicProportion of patientsSocial determinantsReceipt of MOUDHealth AdministrationRecord dataEffect sizeMOUD engagementCalculated proportions
2022
Analysis of Severe Illness After Postvaccination COVID-19 Breakthrough Among Adults With and Without HIV in the US
Lang R, Humes E, Coburn SB, Horberg MA, Fathi LF, Watson E, Jefferson CR, Park LS, Gordon KS, Akgün KM, Justice AC, Napravnik S, Edwards JK, Browne LE, Agil DM, Silverberg MJ, Skarbinski J, Leyden WA, Stewart C, Hogan BC, Gebo KA, Marconi VC, Williams CF, Althoff KN. Analysis of Severe Illness After Postvaccination COVID-19 Breakthrough Among Adults With and Without HIV in the US. JAMA Network Open 2022, 5: e2236397. PMID: 36227594, PMCID: PMC9561947, DOI: 10.1001/jamanetworkopen.2022.36397.Peer-Reviewed Original ResearchConceptsBreakthrough COVID-19Breakthrough infectionsHIV statusCohort studySevere illnessMAIN OUTCOMEBreakthrough SARS-CoV-2 infectionCOVID-19 vaccine typesLow CD4 cell countsSARS-CoV-2 infectionCOVID-19Severe immune suppressionCD4 cell countProportion of patientsCells/μLPrevious COVID-19Additional vaccine dosesProportional hazards modelDiscrete-time proportional hazards modelsRisk reduction recommendationsVaccine guidelinesCD4 cellsCumulative incidenceHazard ratioClinical factorsSARS-CoV-2 Testing and Positivity Among Persons With and Without HIV in 6 US Cohorts
Park LS, McGinnis KA, Gordon KS, Justice AC, Leyden W, Silverberg MJ, Skarbinski J, Jefferson C, Horberg M, Certa J, Napravnik S, Edwards JK, Westreich D, Bastarache L, Gangireddy S, Benning L, D'Souza G, Williams C, Althoff KN. SARS-CoV-2 Testing and Positivity Among Persons With and Without HIV in 6 US Cohorts. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2022, 90: 249-255. PMID: 35195574, PMCID: PMC9203911, DOI: 10.1097/qai.0000000000002943.Peer-Reviewed Original ResearchConceptsSARS-CoV-2SARS-CoV-2 testingHIV statusClinical cohortPositive SARS-CoV-2 testSARS-CoV-2 positivitySARS-CoV-2 testCOVID-19-related outcomesProportion of PWHProportion of patientsSARS-CoV-2 variantsCOVID-19 vaccineLatest therapeutic optionsTherapeutic optionsUS cohortPositivity proportionInterval cohortPWHPWOHCohortHealth systemDiverse cohortHIVPositivityTesting proportions